BBOT (BBOT) Chief Scientific Officer receives new stock options and RSU grants

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. Chief Scientific Officer Pedro Beltran received new equity awards as part of his compensation. He was granted an option for 210,000 shares of common stock at an exercise price of 10.19 per share, vesting in substantially equal monthly installments from January 1, 2026.

He also received 46,670 restricted stock units, each representing one share of common stock. These RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and are settled in shares upon vesting, subject to his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Beltran Pedro

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	210,000	$0.00	--
Grant/Award	Common Stock	46,670	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 210,000 shares (Direct); Common Stock — 46,670 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beltran Pedro

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		46,670(1)	A	$0	46,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.19	03/10/2026		A		210,000		(2)	03/09/2036	Common Stock	210,000	$0	210,000	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Uneek Mehra, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did BBOT Chief Scientific Officer Pedro Beltran receive?

Pedro Beltran received two equity awards: an option for 210,000 shares of common stock and 46,670 restricted stock units. Both awards are compensation grants that vest over time starting from January 1, 2026, contingent on his continued service with BridgeBio Oncology Therapeutics.

How do Pedro Beltran’s new stock options at BBOT vest over time?

The 210,000-share stock option vests in substantially equal monthly installments, with 1/48th of the shares vesting on each monthly anniversary of January 1, 2026. This four-year vesting schedule aligns Beltran’s long-term incentives with the company’s performance while he remains in continuous service.

What are the terms of Pedro Beltran’s restricted stock units in BBOT?

Beltran’s 46,670 restricted stock units each represent a contingent right to receive one share of common stock. They vest in 16 equal quarterly installments over four years from January 1, 2026, and are settled in shares upon vesting, provided he maintains continuous service with the company.

Are Pedro Beltran’s BBOT equity grants open-market purchases or compensation awards?

These are compensation-related awards, not open-market purchases. The Form 4 classifies both the stock option and restricted stock units under a grant or award acquisition code, with a transaction price per share of zero, indicating they were granted by the company as part of his compensation package.

What is the exercise price and expiration date of Pedro Beltran’s BBOT stock option?

The stock option has an exercise price of 10.19 per share and an expiration date of March 9, 2036. Beltran can exercise vested portions of this option before expiration, subject to the company’s equity plan terms and his continued employment conditions outlined in the award agreement.